{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T15:26:27Z","timestamp":1777217187715,"version":"3.51.4"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,11]],"date-time":"2016-04-11T00:00:00Z","timestamp":1460332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Marie Curie Fellowship","award":["658363"],"award-info":[{"award-number":["658363"]}]},{"DOI":"10.13039\/501100000265","name":"MRC","doi-asserted-by":"publisher","award":["MR\/J007897\/1"],"award-info":[{"award-number":["MR\/J007897\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"MRC","doi-asserted-by":"publisher","award":["MR\/N002091\/1"],"award-info":[{"award-number":["MR\/N002091\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006832","name":"Center for HIV\/AIDS Vaccine Immunology and Immunogen Discovery","doi-asserted-by":"publisher","award":["UM1AI100663"],"award-info":[{"award-number":["UM1AI100663"]}],"id":[{"id":"10.13039\/100006832","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Neutralizing Antibody Consortium"},{"name":"Bill and Melinda Gates Collaboration for AIDS Vaccine Discovery"},{"name":"Wellcome Trust Centre","award":["090532\/Z\/09\/Z"],"award-info":[{"award-number":["090532\/Z\/09\/Z"]}]},{"name":"Unither Virology"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.coviro.2016.04.001","type":"journal-article","created":{"date-parts":[[2016,4,25]],"date-time":"2016-04-25T15:48:01Z","timestamp":1461599281000},"page":"70-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Native functionality and therapeutic targeting of arenaviral glycoproteins"],"prefix":"10.1016","volume":"18","author":[{"given":"Max","family":"Crispin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antra","family":"Zeltina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Zitzmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas A","family":"Bowden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2016.04.001_bib0315","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3390\/pathogens4020283","article-title":"Human hemorrhagic fever causing arenaviruses: molecular mechanisms contributing to virus virulence and disease pathogenesis","volume":"4","author":"Shao","year":"2015","journal-title":"Pathogens"},{"key":"10.1016\/j.coviro.2016.04.001_bib0320","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1136\/bmj.311.7009.857","article-title":"Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice","volume":"311","author":"Fisher-Hoch","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/j.coviro.2016.04.001_bib0325","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1472-698X-13-2","article-title":"Housing equity for health equity: a rights-based approach to the control of Lassa fever in post-war Sierra Leone","volume":"13","author":"Kelly","year":"2013","journal-title":"BMC Int Health Hum Rights"},{"key":"10.1016\/j.coviro.2016.04.001_bib0330","doi-asserted-by":"crossref","DOI":"10.1007\/s10393-016-1098-8","article-title":"Rat-atouille: a mixed method study to characterize rodent hunting and consumption in the context of Lassa fever","author":"Bonwitt","year":"2016","journal-title":"EcoHealth"},{"key":"10.1016\/j.coviro.2016.04.001_bib0335","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1007\/s00705-015-2418-y","article-title":"Past, present, and future of arenavirus taxonomy","volume":"160","author":"Radoshitzky","year":"2015","journal-title":"Arch Virol"},{"key":"10.1016\/j.coviro.2016.04.001_sbref0345","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00180-12","article-title":"Identification, characterization, and in vitro culture of highly divergent arenaviruses from boa constrictors and annulated tree boas: candidate etiological agents for snake inclusion body disease","volume":"3","author":"Stenglein","year":"2012","journal-title":"mBio"},{"key":"10.1016\/j.coviro.2016.04.001_sbref0350","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1099\/vir.0.051995-0","article-title":"Detection of novel divergent arenaviruses in boid snakes with inclusion body disease in The Netherlands","volume":"94","author":"Bodewes","year":"2013","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2016.04.001_sbref0355","doi-asserted-by":"crossref","first-page":"10918","DOI":"10.1128\/JVI.01123-13","article-title":"Isolation, identification, and characterization of novel arenaviruses, the etiological agents of boid inclusion body disease","volume":"87","author":"Hetzel","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.04.001_bib0360","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3390\/v4010083","article-title":"The curious case of arenavirus entry, and its inhibition","volume":"4","author":"Nunberg","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2016.04.001_sbref0365","doi-asserted-by":"crossref","first-page":"e1005418","DOI":"10.1371\/journal.ppat.1005418","article-title":"Acidic pH-induced conformations and LAMP1 binding of the Lassa virus glycoprotein spike","volume":"12","author":"Li","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2016.04.001_sbref0370","doi-asserted-by":"crossref","first-page":"7584","DOI":"10.1128\/JVI.00651-15","article-title":"Molecular mechanism for LAMP1 recognition by Lassa virus","volume":"89","author":"Cohen-Dvashi","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.04.001_bib0375","doi-asserted-by":"crossref","first-page":"8259","DOI":"10.1128\/JVI.00761-09","article-title":"Unusual molecular architecture of the machupo virus attachment glycoprotein","volume":"83","author":"Bowden","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.04.001_sbref0380","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.chom.2015.11.005","article-title":"Molecular basis for antibody-mediated neutralization of new world hemorrhagic fever mammarenaviruses","volume":"18","author":"Mahmutovic","year":"2015","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coviro.2016.04.001_sbref0385","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1126\/science.1252480","article-title":"Virus entry. Lassa virus entry requires a trigger-induced receptor switch","volume":"344","author":"Jae","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.coviro.2016.04.001_bib0390","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature05539","article-title":"Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses","volume":"446","author":"Radoshitzky","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2016.04.001_bib0395","doi-asserted-by":"crossref","first-page":"e1000358","DOI":"10.1371\/journal.ppat.1000358","article-title":"Host-species transferrin receptor 1 orthologs are cellular receptors for nonpathogenic New World clade B arenaviruses","volume":"5","author":"Abraham","year":"2009","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2016.04.001_bib0400","doi-asserted-by":"crossref","first-page":"9418","DOI":"10.1128\/JVI.01112-14","article-title":"Human and host species transferrin receptor 1 use by North American arenaviruses","volume":"88","author":"Zong","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.04.001_bib0405","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1126\/science.289.5481.842","article-title":"Emerging diseases. New arenavirus blamed for recent deaths in California","volume":"289","author":"Enserink","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.coviro.2016.04.001_bib0410","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/nsmb.1772","article-title":"Structural basis for receptor recognition by New World hemorrhagic fever arenaviruses","volume":"17","author":"Abraham","year":"2010","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.coviro.2016.04.001_bib0415","doi-asserted-by":"crossref","first-page":"e1000358","DOI":"10.1371\/journal.ppat.1000358","article-title":"Host-species transferrin receptor 1 orthologs are cellular receptors for nonpathogenic New World clade B arenaviruses","volume":"5","author":"Abraham","year":"2009","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2016.04.001_bib0420","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1073\/pnas.0709254105","article-title":"Receptor determinants of zoonotic transmission of New World hemorrhagic fever arenaviruses","volume":"105","author":"Radoshitzky","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2016.04.001_bib0425","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/nsmb.1772","article-title":"Structural basis for receptor recognition by New World hemorrhagic fever arenaviruses","volume":"17","author":"Abraham","year":"2010","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.coviro.2016.04.001_bib0430","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1128\/JVI.03119-14","article-title":"Replication of boid inclusion body disease-associated arenaviruses is temperature sensitive in both boid and mammalian cells","volume":"89","author":"Hepojoki","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.04.001_bib0435","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1128\/JVI.03349-14","article-title":"The Z proteins of pathogenic but not nonpathogenic arenaviruses inhibit RIG-I-like receptor-dependent interferon production","volume":"89","author":"Xing","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.04.001_bib0440","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1126\/science.282.5396.2079","article-title":"Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus","volume":"282","author":"Cao","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.coviro.2016.04.001_bib0445","doi-asserted-by":"crossref","first-page":"5140","DOI":"10.1128\/JVI.76.10.5140-5146.2002","article-title":"World arenavirus clade C, but not clade A and B viruses, utilizes alpha-dystroglycan as its major receptor","volume":"76","author":"Spiropoulou","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.04.001_bib0450","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1083\/jcb.200104103","article-title":"Molecular analysis of the interaction of LCMV with its cellular receptor [alpha]-dystroglycan","volume":"155","author":"Kunz","year":"2001","journal-title":"J Cell Biol"},{"key":"10.1016\/j.coviro.2016.04.001_bib0455","doi-asserted-by":"crossref","first-page":"5979","DOI":"10.1128\/JVI.79.10.5979-5987.2005","article-title":"Characterization of the interaction of Lassa fever virus with its cellular receptor alpha-dystroglycan","volume":"79","author":"Kunz","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.04.001_bib0460","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/j.1462-5822.2007.01113.x","article-title":"Cell entry by human pathogenic arenaviruses","volume":"10","author":"Rojek","year":"2008","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.coviro.2016.04.001_bib0465","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.virol.2003.07.002","article-title":"Alpha-dystroglycan can mediate arenavirus infection in the absence of beta-dystroglycan","volume":"316","author":"Kunz","year":"2003","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2016.04.001_bib0470","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/355696a0","article-title":"Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix","volume":"355","author":"Ibraghimov-Beskrovnaya","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2016.04.001_bib0475","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1242\/jcs.02814","article-title":"Dystroglycan: from biosynthesis to pathogenesis of human disease","volume":"119","author":"Barresi","year":"2006","journal-title":"J Cell Sci"},{"key":"10.1016\/j.coviro.2016.04.001_bib0480","doi-asserted-by":"crossref","first-page":"14282","DOI":"10.1128\/JVI.79.22.14282-14296.2005","article-title":"Posttranslational modification of alpha-dystroglycan, the cellular receptor for arenaviruses, by the glycosyltransferase LARGE is critical for virus binding","volume":"79","author":"Kunz","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.04.001_bib0485","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.1128\/JVI.02574-06","article-title":"Old World and clade C New World arenaviruses mimic the molecular mechanism of receptor recognition used by alpha-dystroglycan's host-derived ligands","volume":"81","author":"Rojek","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.04.001_bib0490","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1128\/JVI.06451-11","article-title":"Identification of cell surface molecules involved in dystroglycan-independent Lassa virus cell entry","volume":"86","author":"Shimojima","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.04.001_bib0495","doi-asserted-by":"crossref","first-page":"13070","DOI":"10.1128\/JVI.02298-13","article-title":"Crystal structure of Venezuelan hemorrhagic fever virus fusion glycoprotein reveals a class 1 postfusion architecture with extensive glycosylation","volume":"87","author":"Parsy","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.04.001_bib0500","doi-asserted-by":"crossref","first-page":"19967","DOI":"10.1073\/pnas.1108910108","article-title":"X-ray structure of the arenavirus glycoprotein GP2 in its postfusion hairpin conformation","volume":"108","author":"Igonet","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2016.04.001_bib0505","doi-asserted-by":"crossref","first-page":"10932","DOI":"10.1128\/JVI.01140-08","article-title":"pH-induced activation of arenavirus membrane fusion is antagonized by small-molecule inhibitors","volume":"82","author":"York","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.04.001_bib0510","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/514749","article-title":"Clinical case definitions for Argentine hemorrhagic fever","volume":"28","author":"Harrison","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2016.04.001_bib0515","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/S0140-6736(79)92335-3","article-title":"Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome","volume":"2","author":"Maiztegui","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2016.04.001_bib0520","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(84)90299-X","article-title":"Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma","volume":"2","author":"Enria","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2016.04.001_bib0525","first-page":"2239","article-title":"[Treatment of Argentine hemorrhagic fever with convalescent's plasma. 4433 cases]","volume":"15","author":"Ruggiero","year":"1986","journal-title":"Presse Med"},{"issue":"Pt 5","key":"10.1016\/j.coviro.2016.04.001_bib0530","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1099\/0022-1317-70-5-1125","article-title":"Junin virus monoclonal antibodies: characterization and cross-reactivity with other arenaviruses","volume":"70","author":"Sanchez","year":"1989","journal-title":"J Gen Vir"},{"key":"10.1016\/j.coviro.2016.04.001_bib0535","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1517\/17460441.2012.687719","article-title":"Drug discovery technologies and strategies for Machupo virus and other New World arenaviruses","volume":"7","author":"Radoshitzky","year":"2012","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.coviro.2016.04.001_bib0540","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02969-15","article-title":"Glycoprotein-specific antibodies produced by DNA vaccination protect guinea pigs from lethal Argentine and Venezuelan hemorrhagic fever","author":"Golden","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.04.001_bib0545","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1086\/514211","article-title":"Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group","volume":"177","author":"Maiztegui","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2016.04.001_bib0550","doi-asserted-by":"crossref","first-page":"e1003212","DOI":"10.1371\/journal.ppat.1003212","article-title":"Vaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trials","volume":"9","author":"Olschlager","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2016.04.001_bib0555","doi-asserted-by":"crossref","first-page":"e1000695","DOI":"10.1371\/journal.ppat.1000695","article-title":"A multivalent and cross-protective vaccine strategy against arenaviruses associated with human disease","volume":"5","author":"Kotturi","year":"2009","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2016.04.001_bib0560","doi-asserted-by":"crossref","first-page":"7373","DOI":"10.1128\/JVI.00307-15","article-title":"Arenavirus genome rearrangement for the development of live attenuated vaccines","volume":"89","author":"Cheng","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.04.001_bib0565","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1128\/JVI.03401-14","article-title":"Development of live-attenuated arenavirus vaccines based on codon deoptimization","volume":"89","author":"Cheng","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.04.001_bib0570","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJM198601023140104","article-title":"Lassa fever. Effective therapy with ribavirin","volume":"314","author":"McCormick","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2016.04.001_bib0575","first-page":"435","article-title":"Lassa immune serum","volume":"55","author":"Clayton","year":"1977","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.coviro.2016.04.001_bib0580","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/0035-9203(85)90388-8","article-title":"Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization","volume":"79","author":"Jahrling","year":"1985","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.coviro.2016.04.001_bib0585","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1016\/j.vaccine.2008.07.057","article-title":"Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates","volume":"26","author":"Lukashevich","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2016.04.001_bib0590","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1128\/JVI.74.15.6777-6783.2000","article-title":"Effective vaccine for Lassa fever","volume":"74","author":"Fisher-Hoch","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.04.001_sbref0595","doi-asserted-by":"crossref","first-page":"e1005276.","DOI":"10.1371\/journal.ppat.1005276","article-title":"Arenavirus glycan shield promotes neutralizing antibody evasion and protracted infection","volume":"11","author":"Sommerstein","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2016.04.001_bib0600","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.coviro.2015.02.002","article-title":"Targeting host-derived glycans on enveloped viruses for antibody-based vaccine design","volume":"11","author":"Crispin","year":"2015","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.coviro.2016.04.001_bib0605","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.1213256","article-title":"A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield","volume":"334","author":"Pejchal","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.coviro.2016.04.001_bib0610","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nsmb.2627","article-title":"Antibodies expose multiple weaknesses in the glycan shield of HIV","volume":"20","author":"Crispin","year":"2013","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.coviro.2016.04.001_bib0615","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1517\/14656566.2.8.1317","article-title":"Ribavirin \u2013 current status of a broad spectrum antiviral agent","volume":"2","author":"Snell","year":"2001","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.coviro.2016.04.001_sbref0620","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.antiviral.2013.03.023","article-title":"Small molecule inhibitors of ER alpha-glucosidases are active against multiple hemorrhagic fever viruses","volume":"98","author":"Chang","year":"2013","journal-title":"Antivir Res"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625716300438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625716300438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T20:58:31Z","timestamp":1567803511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625716300438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":61,"alternative-id":["S1879625716300438"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2016.04.001","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Native functionality and therapeutic targeting of arenaviral glycoproteins","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2016.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}